AB56-ASA1-AA2,38,75
253.06
(5) (e) 3. The summary suspension of authorization of a vendor, infant
6formula supplier, or direct distribution center shall be effective immediately upon
7receipt of the notice under par. (d).
AB56-ASA1-AA2,38,249
253.06
(6) (b) A person may contest an assessment of forfeiture, recoupment
10or enforcement assessment, a denial
, suspension or termination of authorization
, a
11civil monetary penalty assessed in lieu of disqualification, a summary suspension, 12or a
suspension or termination of eligibility by sending a written request for hearing
13under s. 227.44 to the division of hearings and appeals in the department of
14administration within 10 days after the receipt of the notice issued under sub. (3)
15(bm) or (5) (d). The administrator of the division of hearings and appeals may
16designate a hearing examiner to preside over the case and recommend a decision to
17the administrator under s. 227.46. The decision of the administrator of the division
18of hearings and appeals shall be the final administrative decision. The division of
19hearings and appeals shall commence the hearing and issue a final decision within
2060 days after receipt of the request for hearing unless all of the parties consent to a
21later date. Proceedings before the division of hearings and appeals are governed by
22ch. 227. In any petition for judicial review of a decision by the division of hearings
23and appeals, the department, if not the petitioner who was in the proceeding before
24the division of hearings and appeals, shall be the named respondent.
AB56-ASA1-AA2,39,4
1253.06
(8) Inspection of premises. The department may visit and inspect each
2authorized vendor
and infant formula supplier and each
food direct distribution
3center, and for such purpose shall be given unrestricted access to the premises
4described in the authorization or contract.
AB56-ASA1-AA2,39,106
253.06
(9) Confidentiality of applicant and participant information. (a) Any
7information about an applicant or participant, whether it is obtained from the
8applicant or participant or another source or is generated as a result of application
9for the Women, Infants, and Children program, that identifies the applicant or
10participant or a family member of the applicant or participant is confidential.
AB56-ASA1-AA2,39,2011
(b) Except as explicitly permitted under this section, the department shall
12restrict the use and disclosure of confidential applicant and participant information
13to any person directly connected with the administration or enforcement of the
14Women, Infants, and Children program that the department determines has a need
15to know the information for Women, Infants, and Children program purposes.
16Persons who may be allowed to access confidential information under this paragraph
17include personnel from the local agencies, persons under contract with the
18department to perform research regarding the Women, Infants, and Children
19program, and persons that are investigating or prosecuting Women, Infants, and
20Children program violations of federal, state, or local law.
AB56-ASA1-AA2,39,2421
(c) The department or any local agency may use or disclose to public
22organizations confidential applicant and participant information for the
23administration of other programs that serve individuals eligible for the Women,
24Infants, and Children program in accordance with
7 CFR 246.26 (h).
AB56-ASA1-AA2,40,4
1(d) Staff of the department and local agencies who are required by state law to
2report known or suspected child abuse or neglect may disclose confidential applicant
3and participant information without the consent of the participant or applicant to
4the extent necessary to comply with the law.
AB56-ASA1-AA2,40,185
(e) Except in the case of subpoenas or search warrants, the department and
6local agencies may disclose confidential applicant and participant information to
7individuals or entities not listed in this section only if the affected applicant or
8participant signs a release form authorizing the disclosure and specifying the parties
9to which the information may be disclosed. The department or local agency shall
10allow applicants and participants to refuse to sign the release form and shall notify
11the applicant or participant that signing the form is not a condition of eligibility and
12refusing to sign the form will not affect the applicant's or participant's application
13or participation in the Women, Infants, and Children program. Release forms
14authorizing disclosure to private physicians or other health care providers may be
15included as part of the Women, Infants, and Children program application or
16certification process. All other requests for applicants or participants to sign
17voluntary release forms may occur only after the application and certification
18process is complete.
AB56-ASA1-AA2,41,419
(f) The department or local agency shall provide to an applicant or participant
20access to all information he or she has provided to the Women, Infants, and Children
21program. In the case of an applicant or participant who is an infant or child, the
22access may be provided to a parent or guardian of the infant or child, assuming that
23any issues regarding custody or guardianship have been settled. The department or
24local agency is not required to provide the applicant or participant or parent or
25guardian of an infant or child applicant or participant access to any other
1information in the file or record, including documentation of income provided by a
23rd party and staff assessments of an applicant or participant's condition or
3behavior, unless required by law or unless the information supports a state or local
4agency decision being appealed under
7 CFR 246.9.
AB56-ASA1-AA2,41,10
5(10) Confidentiality of vendor information. (a) Any information about a
6vendor, whether it is obtained from the vendor or another source, that individually
7identifies the vendor except for the vendor's name, address, telephone number,
8Internet or electronic mail address, store type, and Women, Infants, and Children
9program authorization status is confidential. The department shall restrict the use
10or disclosure of confidential vendor information to any of the following:
AB56-ASA1-AA2,41,1611
1. Persons directly connected with the administration or enforcement of the
12Women, Infants, and Children program or the food stamp program under s. 49.79
13that the department determines has a need to know the information for purposes of
14these programs. These persons may include personnel from local agencies and
15persons investigating or prosecuting violations of Women, Infants, and Children
16program or food stamp program federal, state, or local laws.
AB56-ASA1-AA2,41,2217
2. Persons directly connected with the administration or enforcement of any
18federal or state law or local ordinance. Before releasing information to a state or local
19entity, the department shall enter into a written agreement with the requesting
20party specifying that the information may not be used or redisclosed except for
21purposes directly connected with the administration or enforcement of the federal or
22state law or local ordinance.
AB56-ASA1-AA2,41,2523
3. A vendor that is subject to an adverse action under sub. (5), including a claim,
24to the extent that the confidential information concerns the vendor that is subject to
25the adverse action and is related to the adverse action.
AB56-ASA1-AA2,42,8
1(b) The department may disclose to all authorized vendors and applicants to
2be a vendor sanctions that have been imposed on vendors if the disclosure identifies
3only the vendor's name, address, length of the disqualification or amount of the
4monetary penalty, and a summary of the reason for the sanction provided in the
5notice of adverse action under sub. (5). The information under this paragraph may
6be disclosed only after all administrative and judicial review is exhausted and the
7department has prevailed regarding the sanction imposed on the vendor or after the
8time period for requesting administrative and judicial review has expired.”.
AB56-ASA1-AA2,42,1111
253.07
(1) (a) 3. Pregnancy termination.
AB56-ASA1-AA2,42,1313
253.07
(1) (b) 3. Pregnancy termination.
AB56-ASA1-AA2,1937w
14Section 1937w. 253.07 (5) (b) (intro.) of the statutes is renumbered 253.07 (5)
15(b) and amended to read:
AB56-ASA1-AA2,42,1916
253.07
(5) (b)
Subject to par. (c), a A public entity that receives women's health
17funds under this section may provide some or all of the funds to other public or
18private entities
provided that the recipient of the funds does not do any of the
19following:.
AB56-ASA1-AA2,43,2
1“254.151
(2m) Award grants for residential lead hazard abatement, residential
2lead hazard reduction, and lead abatement worker training.”.
AB56-ASA1-AA2,43,76
255.06
(2) (i)
Multiple sclerosis services. Allocate and expend
at least
up to 7$60,000 as reimbursement for the provision of multiple sclerosis services to women.”.
AB56-ASA1-AA2,43,11
10632.796 Drug cost report. (1) Definition. In this section, “disability
11insurance policy” has the meaning given in s. 632.895 (1) (a).
AB56-ASA1-AA2,43,17
12(2) Report required. Annually, at the time the insurer files its rate request
13with the commissioner, each insurer that offers a disability insurance policy that
14covers prescription drugs shall submit to the commissioner a report that identifies
15the 25 prescription drugs that are the highest cost to the insurer and the 25
16prescription drugs that have the highest cost increases over the 12 months before the
17submission of the report.
AB56-ASA1-AA2,43,2119
632.865
(3) Registration required. (a) No person may perform any activities
20of a pharmacy benefit manager in this state without first registering with the
21commissioner under this subsection.
AB56-ASA1-AA2,43,2422
(b) The commissioner shall establish a registration procedure for pharmacy
23benefit managers. The commissioner may promulgate any rules necessary to
24implement the registration procedure under this paragraph.
AB56-ASA1-AA2,44,2
2632.866 Prescription drug cost reporting. (1) Definitions. In this section:
AB56-ASA1-AA2,44,43
(a) “Brand-name drug” means a prescription drug approved under
21 USC 355 4(b) or
42 USC 262.
AB56-ASA1-AA2,44,65
(b) “Covered hospital” means an entity described in
42 USC 256b (a) (4) (L) to
6(N) that participates in the federal drug-pricing program under
42 USC 256b.
AB56-ASA1-AA2,44,77
(c) “Disability insurance policy” has the meaning given in s. 632.895 (1) (a).
AB56-ASA1-AA2,44,88
(d) “Generic drug” means a prescription drug approved under
21 USC 355 (j).
AB56-ASA1-AA2,44,119
(e) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer”
10does not include an entity that is engaged only in the dispensing, as defined in s.
11450.01 (7), of a brand-name drug or a generic drug.
AB56-ASA1-AA2,44,1512
(f) “Manufacturer-sponsored assistance program” means a program offered by
13a manufacturer or an intermediary under contract with a manufacturer through
14which a brand-name drug or a generic drug is provided to a patient at no charge or
15at a discount.
AB56-ASA1-AA2,44,1916
(g) “Margin” means, for a covered hospital, the difference between the net cost
17of a brand-name drug or generic drug covered under the federal drug-pricing
18program under
42 USC 256b and the net payment by the covered hospital for that
19brand-name drug or generic drug.
AB56-ASA1-AA2,44,2120
(h) “Net payment” means the amount paid for a brand-name drug or generic
21drug after all discounts and rebates have been applied.
AB56-ASA1-AA2,44,2222
(i) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
AB56-ASA1-AA2,45,223
(j) “Wholesale acquisition cost” means the most recently reported
24manufacturer list or catalog price for a brand-name drug or a generic drug available
1to wholesalers or direct purchasers in the United States, before application of
2discounts, rebates, or reductions in price.
AB56-ASA1-AA2,45,8
3(2) Price increase or introduction notice; justification report. (a) A
4manufacturer shall notify the commissioner if it is increasing the wholesale
5acquisition cost of a brand-name drug on the market in this state by more than 10
6percent or by more than $10,000 during any 12-month period or if it intends to
7introduce to market in this state a brand-name drug that has an annual wholesale
8acquisition cost of $30,000 or more.
AB56-ASA1-AA2,45,129
(b) A manufacturer shall notify the commissioner if it is increasing the
10wholesale acquisition cost of a generic drug by more than 25 percent or by more than
11$300 during any 12-month period or if it intends to introduce to market a generic
12drug that has an annual wholesale acquisition cost of $3,000 or more.
AB56-ASA1-AA2,45,1813
(c) The manufacturer shall provide the notice under par. (a) or (b) in writing
14at least 30 days before the planned effective date of the cost increase or drug
15introduction with a justification that includes all documents and research related to
16the manufacturer's selection of the cost increase or introduction price and a
17description of life cycle management, market competition and context, and
18estimated value or cost-effectiveness of the product.
AB56-ASA1-AA2,45,22
19(3) Net prices paid by pharmacy benefit managers. By March 1 annually, the
20manufacturer shall report to the commissioner the value of price concessions,
21expressed as a percentage of the wholesale acquisition cost, provided to each
22pharmacy benefit manager for each drug sold in this state.
AB56-ASA1-AA2,46,2
23(4) Rebates and price concessions. By March 1 annually, each pharmacy
24benefit manager shall report to the commissioner the amount received from
25manufacturers as drug rebates and the value of price concessions, expressed as a
1percentage of the wholesale acquisition cost, provided by manufacturers for each
2drug.
AB56-ASA1-AA2,46,7
3(5) Hospital margin spending. By March 1 annually, each covered hospital
4operating in this state shall report to the commissioner the per unit margin for each
5drug covered under the federal drug pricing program under
42 USC 256b dispensed
6in the previous year multiplied by the number of units dispensed at that margin and
7how the margin revenue was used.
AB56-ASA1-AA2,46,11
8(6) Manufacturer-sponsored assistance programs. By March 1 annually,
9each manufacturer shall provide the commissioner with a description of each
10manufacturer-sponsored patient assistance program in effect during the previous
11year that includes all of the following:
AB56-ASA1-AA2,46,1212
(a) The terms of the programs.
AB56-ASA1-AA2,46,1313
(b) The number of prescriptions provided to state residents under the program.
AB56-ASA1-AA2,46,1514
(c) The total market value of assistance provided to residents of this state under
15the program.
AB56-ASA1-AA2,46,20
16(7) Certification and penalties for noncompliance. Each manufacturer and
17covered hospital that is required to report under this section shall certify each report
18as accurate under the penalty of perjury. A manufacturer or covered hospital that
19fails to submit a report required under this section is subject to a forfeiture of no more
20than $10,000 each day the report is overdue.
AB56-ASA1-AA2,46,24
21(8) Hearing and public reporting. (a) The commissioner shall publicly post
22manufacturer price justification documents and covered hospital documentation of
23how each hospital spends the margin revenue. The commissioner shall keep any
24trade secret or proprietary information confidential.
AB56-ASA1-AA2,47,8
1(b) The commissioner shall analyze data collected under this section and
2publish annually a report on emerging trends in prescription prices and price
3increases, and shall annually conduct a public hearing based on the analysis under
4this paragraph. The report under this paragraph shall include analysis of
5manufacturer prices and price increases, analysis of hospital-specific margins and
6how that revenue is spent or allocated on a hospital-specific basis, and analysis of
7how pharmacy benefit manager discounts and net costs compare to retail prices paid
8by patients.
AB56-ASA1-AA2,47,17
9(9) Allowing cost disclosure to insured. The commissioner shall ensure that
10every disability insurance policy that covers prescription drugs or biological products
11does not restrict a pharmacy or pharmacist that dispenses a prescription drug or
12biological product from informing and does not penalize a pharmacy or pharmacist
13for informing an insured under a policy of a difference between the negotiated price
14of, or copayment or coinsurance for, the drug or biological product under the policy
15and the price the insured would pay for the drug or biological product if the insured
16obtained the drug or biological product without using any health insurance
17coverage.”.
AB56-ASA1-AA2,47,21
21“(4f)
Psychiatric care technicians; pay increases.
AB56-ASA1-AA2,47,2222
(a) In this subsection:
AB56-ASA1-AA2,48,223
1. “Psychiatric care technician” means an individual classified as a psychiatric
24care technician who is employed by the state and whose principal duties are
1performing individual treatment programming and maintaining internal security
2among individuals who are committed to any of the following:
AB56-ASA1-AA2,48,33
a. The secure mental health facility established under s. 46.055.
AB56-ASA1-AA2,48,44
b. The Wisconsin Resource Center established under s. 46.056.
AB56-ASA1-AA2,48,55
c. The Mendota Juvenile Treatment Center established under s. 46.057.
AB56-ASA1-AA2,48,66
d. The Winnebago Mental Health Institute.
AB56-ASA1-AA2,48,117
2. “Psychiatric care technician-advanced” means an individual classified as a
8psychiatric care technician-advanced who is employed by the state and whose
9principal duties are performing individual treatment programming and
10maintaining internal security among individuals who are committed to any of the
11following:
AB56-ASA1-AA2,48,1212
a. The secure mental health facility established under s. 46.055.
AB56-ASA1-AA2,48,1313
b. The Wisconsin Resource Center established under s. 46.056.
AB56-ASA1-AA2,48,1414
c. The Mendota Juvenile Treatment Center established under s. 46.057.
AB56-ASA1-AA2,48,1515
d. The Winnebago Mental Health Institute.
AB56-ASA1-AA2,48,1916
(b) The administrator of the division of personnel management in the
17department of administration shall specify in the compensation plan under s. 230.12
18for the 2019-21 biennium that the minimum starting wage for psychiatric care
19technicians is $19 per hour.
AB56-ASA1-AA2,48,2320
(c) The administrator of the division of personnel management in the
21department of administration shall specify in the compensation plan under s. 230.12
22for the 2019-21 biennium that the minimum starting wage for psychiatric care
23technicians-advanced is $19.91 per hour.
AB56-ASA1-AA2,49,224
(d) The administrator of the division of personnel management shall specify in
25the compensation plan under s. 230.12 for the 2019-21 biennium that the wage for
1current psychiatric care technicians is increased by $2.35 per hour, and the wage for
2current psychiatric care technicians-advanced is increased by $2.46 per hour.
AB56-ASA1-AA2,49,93
(e) If, on the effective date of this paragraph, the compensation plan under s.
4230.12 has been adopted for the 2019-21 biennium and the compensation plan does
5not include the minimum hourly pay required under pars. (b) to (d), by no later than
630 days after the effective date of this paragraph, the administrator of the division
7of personnel management in the department of administration shall propose an
8amendment under s. 230.12 (3) (c) to include the minimum hourly pay required
9under pars. (b) to (d) in the compensation plan for the 2019-21 biennium.
AB56-ASA1-AA2,49,1010
(5f)
Correctional officers and youth counselors; pay increases.
AB56-ASA1-AA2,49,1111
(a) In this section:
AB56-ASA1-AA2,49,1312
1. “Correctional officer” means an individual classified as a correctional officer
13who is employed by the state and whose principal duty is any of the following:
AB56-ASA1-AA2,49,1414
a. The supervision of inmates at a prison, as defined in s. 302.01.